|
October 10, 2022
|
Biora Therapeutics to Participate in 12th Annual Partnership Opportunities in Drug Delivery Conference
|
|
September 13, 2022
|
Biora Therapeutics Announces Issuance of Key Patent for Oral Delivery of GLP-1 Receptor Agonists
|
|
September 7, 2022
|
Biora Therapeutics Appoints Dr. Bruce Sands as Chair of its Clinical Advisory Board
|
|
September 6, 2022
|
Biora Therapeutics to Participate in Upcoming H.C. Wainwright Investment Conference
|
|
August 15, 2022
|
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
|
|
August 10, 2022
|
Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform
|
|
August 8, 2022
|
Biora Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update
|
|
August 3, 2022
|
Biora Therapeutics Announces Five Abstracts Accepted at American College of Gastroenterology Annual Scientific Meeting 2022
|
|
July 26, 2022
|
Biora Therapeutics to Participate in Upcoming BTIG Investment Conference
|
|
July 14, 2022
|
Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at Controlled Release Society 2022
|